Earnings Per Share Trends in Actinium Pharmaceuticals (NYSE:ATNM)

2 min read | May 19, 2025 01:14 AM PDT | By Team Kalkine Media

Google News:

Earnings Per Share Trends in Actinium Pharmaceuticals (NYSE:ATNM) — Image source: shutterstock

Recent News

JPMorgan (NYSE:JPM) Leads Quiet Rotation In Financial Value Stocks

Exxon Mobil (NYSE:XOM) In Focus: What’s Catching Market Attention?

UnitedHealth (NYSE:UNH) Leads Healthcare Value Watch

Duke Energy (NYSE:DUK) Dividends Face A Key Market Test

Make Kalkine Media
My Trusted Source

Highlights

Dimensional Fund Advisors notably decreased its shares in Actinium Pharmaceuticals.

Renaissance Technologies and JPMorgan Chase significantly increased their stakes.

The stock’s average rating remains at with fluctuating market performance.

Actinium Pharmaceuticals (NYSE:ATNM) operates within the healthcare sector and is listed on Earnings Per Share. The company is recognized for its focus on developing targeted radiotherapy treatments, with a flagship product aimed at addressing difficult blood cancers. Recent activity in major fund holdings reflects shifting positions among prominent financial entities.

Institutional Share Changes

During the last quarter, Dimensional Fund Advisors reduced its stake in Actinium Pharmaceuticals by a substantial margin, decreasing the total shares it controls. Meanwhile, Renaissance Technologies increased its ownership considerably, adding a significant number of shares. JPMorgan Chase showed the most notable increase, expanding its position by a very large percentage, indicating a marked interest from this financial entity.

Analyst Ratings and Market Performance

Actinium Pharmaceuticals carries an average rating categorized as from market watchers, with some entities offering differing views on the stock's outlook. The stock price has experienced wide variation within the past year, moving between a low point and a peak that reflects market volatility. The company’s market value remains relatively modest compared to larger peers in the sector. It also shows a negative price-to-earnings ratio, a common feature among firms in developmental or specialized pharmaceutical areas.

Company Focus and Sector Context

The company’s primary focus is on radiotherapy products designed to improve patient outcomes in hematologic cancers, (NYSE:ATNM) specifically relapsed and refractory acute myeloid leukemia. Actinium Pharmaceuticals’ ongoing development programs are pivotal in its profile. Its position on the Best Dividend Stocks its status as a mid-sized firm with a specialized pipeline in the biopharmaceutical arena.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.